Published in BJU Int on June 24, 2009
Effects of 1α,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer (2011) 1.20
Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer. Int J Biol Sci (2014) 1.07
Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res (2011) 1.02
Androgen receptor molecular biology and potential targets in prostate cancer. Ther Adv Urol (2010) 0.98
Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer. Genes Cancer (2011) 0.96
Mouse models of prostate cancer: picking the best model for the question. Cancer Metastasis Rev (2014) 0.93
Disease pathways at the Rat Genome Database Pathway Portal: genes in context-a network approach to understanding the molecular mechanisms of disease. Hum Genomics (2014) 0.84
Prostate Cancer Stem Cells: Research Advances. Int J Mol Sci (2015) 0.84
The nrf1 and nrf2 balance in oxidative stress regulation and androgen signaling in prostate cancer cells. Cancers (Basel) (2010) 0.83
Current status of 5α-reductase inhibitors in prostate disease management. Korean J Urol (2013) 0.80
The antiandrogenic effect of finasteride against a mutant androgen receptor. Cancer Biol Ther (2011) 0.80
Steroidogenic factor 1 promotes aggressive growth of castration-resistant prostate cancer cells by stimulating steroid synthesis and cell proliferation. Endocrinology (2013) 0.79
Serum testosterone plays an important role in the metastatic ability of castration resistant prostate cancer. World J Urol (2012) 0.78
Nrf1 and Nrf2 transcription factors regulate androgen receptor transactivation in prostate cancer cells. PLoS One (2014) 0.78
Can glycoprofiling be helpful in detecting prostate cancer? (2014) 0.76
The role of androgen receptor expression in the curative treatment of prostate cancer with radiotherapy: a pilot study. Biomed Res Int (2015) 0.76
MicroRNA Library-Based Functional Screening Identified Androgen-Sensitive miR-216a as a Player in Bicalutamide Resistance in Prostate Cancer. J Clin Med (2015) 0.75
Grappling with the androgen receptor: a new approach for treating advanced prostate cancer. Cancer Cell (2010) 0.75
Key targets of hormone treatment of prostate cancer. Part I: the androgen receptor and steroidogenic pathways. BJU Int (2009) 0.75
Short hairpin RNA library-based functional screening identified ribosomal protein L31 that modulates prostate cancer cell growth via p53 pathway. PLoS One (2014) 0.75
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst (2003) 11.27
Quality-of-life effects of prostate-specific antigen screening. N Engl J Med (2012) 7.21
Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol (2007) 6.23
Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol (2012) 4.48
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int (2008) 3.94
A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol (2010) 3.79
Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol (2012) 3.34
Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. J Natl Cancer Inst (2007) 3.26
A framework for the identification of men at increased risk for prostate cancer. J Urol (2009) 3.07
Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol (2008) 2.92
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res (2010) 2.87
Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol (2009) 2.72
The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. Eur Urol (2006) 2.71
Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol (2011) 2.68
Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review. Eur Urol (2008) 2.66
Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol (2008) 2.65
Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol (2010) 2.55
Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol (2008) 2.55
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51
Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. Eur Urol (2013) 2.43
Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res (2010) 2.39
Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med (2008) 2.33
Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol (2009) 2.31
High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer. Genes Chromosomes Cancer (2005) 2.25
The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer (2010) 2.15
A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol (2009) 2.02
Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam). Eur Urol (2008) 1.94
No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer. BJU Int (2010) 1.94
Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer (2005) 1.93
The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam. Eur Urol (2008) 1.92
Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer (2002) 1.89
Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam. Eur Urol (2011) 1.83
Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol (2006) 1.80
Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review. Eur Urol (2010) 1.66
Risk-based prostate cancer screening. Eur Urol (2011) 1.64
Gleason score, age and screening: modeling dedifferentiation in prostate cancer. Int J Cancer (2006) 1.64
Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology (2005) 1.63
Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int (2012) 1.62
Do anxiety and distress increase during active surveillance for low risk prostate cancer? J Urol (2010) 1.61
Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins. Eur Urol (2008) 1.58
Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol (2007) 1.57
High-resolution analysis of paraffin-embedded and formalin-fixed prostate tumors using comparative genomic hybridization to genomic microarrays. Am J Pathol (2003) 1.57
Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study. BJU Int (2009) 1.56
ERSPC and PLCO prostate cancer screening studies: what are the differences? Eur Urol (2010) 1.55
Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Eur Urol (2006) 1.54
Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies. Eur Urol (2010) 1.54
A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam. Eur Urol (2012) 1.52
Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam. Urology (2006) 1.51
Anxiety and distress during active surveillance for early prostate cancer. Cancer (2009) 1.49
The influence of family history on prostate cancer risk: implications for clinical management. BJU Int (2010) 1.48
Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst (2003) 1.46
hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml. Eur Urol (2007) 1.45
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2011) 1.42
Overall and disease-specific survival of patients with screen-detected prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam. Eur Urol (2006) 1.42
Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer (2002) 1.41
Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. Eur J Cancer (2009) 1.41
The REDUCE Trial. Eur Urol (2010) 1.39
Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk? BJU Int (2013) 1.39
ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol (2011) 1.31
Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol (2011) 1.29
Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol (2002) 1.28
The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison. BJU Int (2008) 1.28
Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature. Eur Urol (2010) 1.28
Towards an optimal interval for prostate cancer screening. Eur Urol (2011) 1.27
A graphical device to represent the outcomes of a logistic regression analysis. Prostate (2008) 1.25
A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res (2010) 1.24
Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening. Eur Urol (2007) 1.18
Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur J Cancer (2006) 1.18
Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Int J Cancer (2003) 1.18
Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). Urology (2005) 1.16
Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J Urol (2008) 1.13
Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes? Cancer (2010) 1.13
Prostate cancer diagnosis: the impact on patients' mental health. Eur J Cancer (2005) 1.11
Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam. J Urol (2005) 1.08
Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations. Cancer (2007) 1.04
Combined lycopene and vitamin E treatment suppresses the growth of PC-346C human prostate cancer cells in nude mice. J Nutr (2006) 1.04
Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology (2004) 1.02
Evaluation of genetic patterns in different tumor areas of intermediate-grade prostatic adenocarcinomas by high-resolution genomic array analysis. Genes Chromosomes Cancer (2004) 1.02
Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant? BJU Int (2005) 1.01
Can the prostate risk calculator based on Western population be applied to Asian population? Prostate (2011) 1.00
Should pathologists routinely report prostate tumour volume? The prognostic value of tumour volume in prostate cancer. Eur Urol (2009) 0.99
Lesions predictive for prostate cancer in a screened population: first and second screening round findings. Prostate (2004) 0.97
Dietary intervention in prostate cancer patients: PSA response in a randomized double-blind placebo-controlled study. Int J Cancer (2005) 0.95
Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation. Prostate (2002) 0.95
Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men. BJU Int (2009) 0.94
Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2012) 0.94
Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population. J Urol (2006) 0.94
False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up. Am J Surg Pathol (2010) 0.93
Should we replace the Gleason score with the amount of high-grade prostate cancer? Eur Urol (2006) 0.93
Prostate cancer: a serious disease suitable for prevention. BJU Int (2009) 0.92
Screening for prostate cancer in Dutch hereditary prostate cancer families. Int J Cancer (2008) 0.92
Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial. J Med Screen (2013) 0.92
Does "normal" aging imply urinary, bowel, and erectile dysfunction? A general population survey. Urology (2008) 0.92
Genetic evaluation of localized prostate cancer in a cohort of forty patients: gain of distal 8q discriminates between progressors and nonprogressors. Lab Invest (2003) 0.92
The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer. BJU Int (2008) 0.90